Analyst Reco. Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Real-time Estimate Cboe BZX Other stock markets 19:22:02 29/04/2024 BST			5-day change	1st Jan Change
38.57 ^USD	+0.76%		-1.03%	-16.01%

04-18	Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	MT
04-01	Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	04-18	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $735,600, According to a Recent SEC Filing	03-22	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $707,005, According to a Recent SEC Filing	03-22	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $627,520, According to a Recent SEC Filing	03-20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT
Goldman Sachs Raises Price Target on Rhythm Pharmaceuticals to $52 From $42, Maintains Buy Rating	01-25	MT
Needham Raises Price Target on Rhythm Pharmaceuticals to $50 From $45, Maintains Buy Rating	01-04	MT
Morgan Stanley Upgrades Rhythm Pharmaceuticals to Overweight From Equalweight, Raises Price Target to $55 From $29	12-19	MT
Wells Fargo Raises Rhythm Pharmaceuticals Price Target to $53 From $48, Maintains Overweight Rating	12-19	MT
Goldman Sachs Raises Price Target on Rhythm Pharmaceuticals to $42 From $38, Maintains Buy Rating	12-07	MT
Needham Raises Rhythm Pharmaceuticals Price Target to $45 From $32, Maintains Buy Rating	12-07	MT
Morgan Stanley Adjusts Rhythm Pharmaceuticals' Price Target to $29 From $28, Keeps Equalweight Rating	10/10/23	MT
BofA Securities Upgrades Rhythm Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $27 From $22	02/08/23	MT
Goldman Sachs Raises Rhythm Pharmaceuticals' Price Target to $45 From $40, Maintains Buy Rating	02/03/23	MT
Canaccord Genuity Adjusts Price Target on Rhythm Pharmaceuticals to $56 From $52, Keeps Buy Rating	02/03/23	MT
Morgan Stanley Adjusts Price Target on Rhythm Pharmaceuticals to $28 From $26, Keeps Equalweight Rating	02/03/23	MT
Goldman Sachs Raises Rhythm Pharmaceuticals' Price Target to $40 From $35, Maintains Buy Rating	26/01/23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Rhythm Pharmaceuticals, Inc.

Equities

RYTM

US76243J1051

Analyst Reco.

Filters